Plerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs. - Wikidata - awgldk - TriplyDB

Plerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs.

Plerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs.

http://www.wikidata.org/entity/Q37785509

about

Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.The evolving role of plerixafor in hematopoietic progenitor cell mobilization.Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients.Cost analysis of a randomized stem cell mobilization study in multiple myeloma.UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy.

P2860

Q34454624-1FD6D75F-31F9-4B60-BDB1-2B745006DD5B Q37921284-9059B533-547D-48CF-B22A-1059C24A1B6E Q38077807-721DD339-BEAA-46AE-A6D4-D02F59F3359B Q38160461-C471C9D8-AEFD-43DE-B916-0E4ADE702E8C Q47256928-3A025ADF-9A44-440A-889E-322ED2808D65 Q48130246-AC3C0395-3B7F-4173-AAAC-F208DD701595 Q48251584-21D545AF-DBFC-4155-8A41-ADED30D8EC2F

P2860

Plerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs.

http://www.wikidata.org/entity/Q37785509

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Plerixafor mobilization leads ...... ults in greater storage costs.

@en

Plerixafor mobilization leads ...... ults in greater storage costs.

@nl

type

label

Plerixafor mobilization leads ...... ults in greater storage costs.

@en

Plerixafor mobilization leads ...... ults in greater storage costs.

@nl

prefLabel

Plerixafor mobilization leads ...... ults in greater storage costs.

@en

Plerixafor mobilization leads ...... ults in greater storage costs.

@nl

P1433

Q37785509-A7EC3D81-02FF-447E-8C0C-B0B9264D3A9A

P1476

Q37785509-A2AE0F6B-FF0F-4454-B5BB-17E43A86A86F

P2093

Q37785509-30E1E460-EF5B-49C5-8B87-2F86416CBFDA

Q37785509-46BCB8B0-BB11-48F8-9EB5-8D205CA85A6F

Q37785509-4E07C9D6-DE26-4C13-88DD-135EFD5D0F76

Q37785509-4F8593D3-464B-4851-9FBE-E7876C51E17B

Q37785509-6096060F-99E3-477D-8BD0-BB0E2DD75AF2

Q37785509-73EA334C-2FA1-41B5-95C7-7A3CD35D492D

Q37785509-A07DB0A2-C78C-4520-AA44-B5C76C1E5CE0

Q37785509-FEC486DD-ED46-42AF-B416-6559FCBE6CBD

P2860

Q37785509-2AFE1259-C0B5-42D7-9A10-D59788A107AD

Q37785509-350C2FBD-1173-480D-8D1F-C8ED2E511FB5

Q37785509-422A2021-071E-4E1C-92F3-ECCE96DFB512

Q37785509-454CC791-96C0-44EE-AC72-A8FB69C1303A

Q37785509-46705AA4-B705-446C-891D-A153C27DB35B

Q37785509-6063491E-50BE-480A-8420-99AE19CE2A52

Q37785509-90E94705-2F50-419F-8CC9-C72DC6CFC8A3

Q37785509-9A65411B-DF19-49CA-935A-91D343109D59

Q37785509-9B624BEB-4864-440C-BB06-ED45A3193528

Q37785509-B05B6F80-C74B-44CB-BB95-8D06E745FF78

P304

Q37785509-C598481D-5006-41C7-8969-FEC7730689A9

P31

Q37785509-27FE1189-0BC3-4F8C-B4E4-9A7FFFCCB333

P356

Q37785509-FE68CC27-913C-4945-B3E3-07C9A520CD5F

P433

Q37785509-0765458B-4ECC-4B58-AD18-5BC92C1CBC98

P478

Q37785509-EBC226A8-C699-4AB7-BB1D-C5518EE16A8B

P577

Q37785509-28974CAA-D927-4AE6-BC82-B5FEC0BE7C4E

P5875

Q37785509-6AC61F9B-9FE2-475E-9C77-2E6DEDD80792

P698

Q37785509-18948D2A-1E8F-4B49-A807-9F095F9FC595

P932

Q37785509-F2C1A8C5-FFAA-46E4-B2CB-84D560B1F142

P356

P1433

Journal of Clinical Apheresis

P1476

Plerixafor mobilization leads ...... ults in greater storage costs.

@en

P2093

Christa Eisenmann

http://www.w3.org/2001/XMLSchema#string

Deborah Magee

http://www.w3.org/2001/XMLSchema#string

Edward A Stadtmauer

http://www.w3.org/2001/XMLSchema#string

Jill Adamski

http://www.w3.org/2001/XMLSchema#string

Kathleen Cunningham

http://www.w3.org/2001/XMLSchema#string

Mary Sell

http://www.w3.org/2001/XMLSchema#string

Una O'Doherty

http://www.w3.org/2001/XMLSchema#string

Yvette C Tanhehco

http://www.w3.org/2001/XMLSchema#string

P2860

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data.

Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.

Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy.

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.

Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures.

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.

A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study.

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.

P304

202-208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCA.20239

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46150078

http://www.w3.org/2001/XMLSchema#string

P698

20818715

http://www.w3.org/2001/XMLSchema#string

P932

3673711

http://www.w3.org/2001/XMLSchema#string